source
- BMS's Krazati fails confirmatory colorectal cancer trial, jeopardizing its accelerated approvalBristol Myers Squibb said its drug Krazati did not meet the primary endpoint in a confirmatory study for second‑line colorectal cancer. The trial was required to verify the benefit that earned the…
- House panel urges FDA to bar Chinese clinical trial data from drug applicationsA House spending committee introduced language urging the FDA to prohibit the use of clinical trial data generated in China when reviewing new drug applications. The proposal reflects concerns abo…